Rak prostate je najpogostejši rak pri moških v Sloveniji.
Diagnosticiramo približno 1600 primerov letno.
udeležencev v kliničnih študijah
odkritih več agresivnih oblik
manj agresivnih oblik raka
• Določitev vrednosti PSA smo do sedaj uporabljali za zgodnje odkrivanje raka prostate. Vrednost PSA ni povišana samo pri raku prostate ampak je lahko povišana vrednost tudi zaradi drugih razlogov (vnetje, nerakave spremembe na prostati, napor…)
• Mnogi visoko agresivni raki prostate sploh ne povišajo vrednosti PSA.
• Povišane vrednosti PSA lahko vodijo do pretirane diagnostike, ker s PSA ne moremo razlikovati med benignimi boleznimi in rakom prostate.
• Diagnostična biopsija prostate je neprijeten invazivnen posegm, zato mora biti sum na raka utemeljen. Nepravilno postavljena diagnoza lahko povzroči nepotrebne biopsije, ki povečajo tveganje za zaplete.
Test Stockholm 3 združuje določitev vrednosti PSA s tremi proteinskimi in s številnimi genetskimi označevalci raka prostate ter kliničnimi podatki o pacientu. Ta kombinacija omogoča natančnejšo oceno tveganja kot PSA. Rezultati so prilagojeni posamezniku, ker temeljijo na podatkih vsakega posameznega bolnika.
Stockholm3 bolje prepozna moške z visokim tveganjem, ki imajo nizke vrednosti PSA, kar omogoča zgodnejše nadaljnje preiskave in preprečuje zamudo pri postavitvi diagnoze. Rezultati se analizirajo s pomočjo posebno razvitega algoritma in vključujejo priporočila za nadaljnje diagnostične korake.
Test Stockholm3 združuje proteinske označevalce (PSA, PSP94, GDF15 in KLK2), številne genetske označevalce in klinične podatke (starost, družinska anamneza raka prostate, predhodne biopsije, uporaba inhibitorjev 5-alfa reduktaze) v en algoritem.
Test Stockholm3 meri številne genetske označevalce – t. i. enojne nukleotidne polimorfizme (SNP), ki vplivajo na tveganje za raka prostate.
Analiza beljakovinskih označevalcev (skupni PSA, prosti PSA, PSP94, GDF15 in KLK2) izboljša oceno tveganja za prisotnost raka prostate.
Pri izračunu Stockholm3 ocene tveganja se upoštevajo tudi naslednji podatki:
• Starost
• Družinska anamneza (oče, brat ali sin z rakom prostate)
• Predhodne biopsije
• Uporaba inhibitorjev 5-alfa reduktaze
Stockholm3 pomaga bolje razumeti individualno tveganje za raka prostate in s tem zmanjšuje negotovost pri bolnikih.
Test Stockholm3 izračuna verjetnost, da ima posameznik agresivnega raka prostate. Rezultat vključuje odstotek verjetnosti za prisotnost klinično pomembnega raka prostate (Gleason Score ≥3+4=7 / ISUP ≥2).
Visoko tveganje:
nadaljnja obravnava pri urologu
Nizko tveganje:
ponovi test na 2-6 let
Stockholm3 test je namenjen moškim med 45 in 74 letom starosti, ki še niso imeli raka prostate in imajo vredost PSA nad 1,5ng/ml.
Zavedamo se, da se ob skrbi za zdravje pogosto pojavijo vprašanja, zato smo vam na voljo za vsa dodatna pojasnila in strokovno pomoč. Lahko nas pokličete vsak delovnik, od ponedeljka do petka, med 08.00 in 18.00 uro. Kadar koli pa nam lahko pišete tudi na elektronski naslov info@stockholm3.si, kjer vam bomo odgovorili v najkrajšem možnem času.
Posebna priprava za test Stockholm3 ni potrebna. Pred testom je priporočeno izogibanje intenzivnemu kolesarjenju in spolnim odnosom. V kolikor imate aktivno okužbo sečil ali prostate, opravite odvzem krvi po zaključenem antibiotičnem zdravljenju. Za test vam ni potrebno biti tešč.
Test Stockholm 3 lahko opravite:
· Synevo Adria Lab (vse enote po Sloveniji, v času delovnih ur, brez prehodnega naročanja)
· Aristotel zdravstveni center
· Barsos MC
· NYD klinika
· Medur
· Urologija d.o.o.
· Ambulanta Fabris
Rezultati so na voljo v 2-3 tednih od odvzema krvi.
Test Stockholm3 so razvili znanstveniki na vodilni švedski medicinski fakulteti - Karolinska inštitut. Test je bil validiran na podlagi raziskav na več kot 90000 moških.
Izvid vašega testa bo pokazal, ali imate nizko ali povišano tveganje za raka prostate. V primeru nizkega tveganja vam bodo ponovno testiranje svetovali čez dve oziroma šest let. Če bo tveganje povišano, pa vam bo po posvetu z lečečim zdravnikom urologom svetovana nadaljnja diagnostika: magnetna resonanca ali biopsija prostate.
Za vsa vprašanja glede naročanja testa in vzpostavitve sodelovanja smo vam na voljo vsak delovnik, od ponedeljka do petka, med 8.00 in 18.00 uro. Dosegljivi smo na telefonski številki 031360996, kadar koli pa nam lahko pišete tudi na elektronski naslov info@stockholm3.si, kjer vam bomo odgovorili v najkrajšem možnem času.
1. Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology. 2015
Nordström et al. Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies. The Lancet Oncology. 2021
Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology. 2018
Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. SJPHC. 2020
Palsdottir, T et. al. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics – Real world evidence from 2018 to 2022. European Urology Opean Science. 2024 Jan 25
Elyan et al. Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort. Eur Urol Focus. 2023 Oct 7
Fredsoe et al. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. Eur Urol Oncol. 2023 Oct
Vigneswaran et al. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Jul 22
Tilki et al. External Validation of Stockholm3 in a Retrospective German Clinical Cohort. Eur Urol Focus. 2024 Aug 6
2. Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. SJPHC. 2020
Palsdottir, T et. al. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics – Real world evidence from 2018 to 2022. European Urology Opean Science. 2024 Jan 25
3. Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology. 2015
Eklund et al. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. European Urology Focus. 2016
Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology. 2018
Waldén M et al. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. European Urology Open Science. 2022
Vigneswaran et al. Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial. JCO supplements, ASCO-GU 2024 presentation, 2024, Jan 25. Vigneswaran et al. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Jul 22
Tilki et al. External Validation of Stockholm3 in a Retrospective German Clinical Cohort. Eur Urol Focus. 2024 Aug 6
4. Bergman et al. Structured care for men who want to get tested for prostate cancer – findings from Capio Prostate Cancer Center. Läkartidningen. 2018;115:FCDT
Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. SJPHC. 2020, Söderbäck et al. Improved prostate cancer diagnostics with a structured pathway including Stockholm 3 test, MRI and targeted perineal biopsies. Läkartidningen. 2023
Mcleod et al. Cost Effectiveness of Prostate Cancer Testing incorporating Stockholm3 and MRI versus standard of care. EAU 2024, April 7
Hao S et al. Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. European Urology. 2022.
5. Thompson et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. NEJM 2004
Naji et al. Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. Ann Fam Med, 2018
Krilaviciute et al. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. European Urology Oncology, 2023
6. Eggener S. Comment - Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Urol Oncol. 2017 Mar
7. Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology. 2015
Nordström et al. Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies. The Lancet Oncology. 2021
Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology. 2018
Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. SJPHC. 2020
Palsdottir, T et. al. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics – Real world evidence from 2018 to 2022. European Urology Opean Science. 2024 Jan 25
Elyan et al. Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort. Eur Urol Focus. 2023 Oct 7
Fredsoe et al. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. Eur Urol Oncol. 2023 Oct
Vigneswaran et al. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Jul 22
Tilki et al. External Validation of Stockholm3 in a Retrospective German Clinical Cohort. Eur Urol Focus. 2024 Aug 6
Vigneswaran et al. Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial. JCO supplements, ASCO-GU 2024 presentation, 2024, Jan 25
Waldén M et al. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. European Urology Open Science. 2022
Söderbäck et al. Improved prostate cancer diagnostics with a structured pathway including Stockholm 3 test, MRI and targeted perineal biopsies. Läkartidningen. 2023,
Mcleod et al. Cost Effectiveness of Prostate Cancer Testing incorporating Stockholm3 and MRI versus standard of care. EAU 2024, April 7
Hao S et al. Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. European Urology. 2022
Mottet et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021
Wei, J.T., et al., Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol, 2023.
8. Thompson et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. NEJM 2004
Hamdy et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. NEJM, 2023
Loeb, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013
9. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763. PMID: 36633525, Cancer Facts and Figures, American Cancer Society, 2023
10. Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. SJPHC. 2020
Palsdottir, T et. al. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics – Real world evidence from 2018 to 2022. European Urology Opean Science. 2024 Jan 25
O PODJETJU C&J MEDICAL
Podjetje C&J Medical s sedežem v Kranju, Gosposvetska 10a, sta ustanovila asist. Jošt Janša, dr. med., spec. urologije, in asist. Cene Kopač, dr. med., spec. travmatologije, z namenom, da slovenskim pacientom omogočita dostop do sodobnih, varnih in strokovno utemeljenih diagnostičnih pristopov. Pri strokovni in operativni podpori projekta sodeluje tudi diplomirana medicinska sestra z dolgoletnimi izkušnjami v uroloških in drugih specialističnih ambulantah, kar dodatno zagotavlja visoko raven strokovnosti in kakovosti pri uvajanju novih diagnostičnih rešitev.
